Hepatitis E Diagnostic Tests Market

Hepatitis E Diagnostic Tests Market Analysis and Forecast by Fact.MR

• The global hepatitis E diagnostic tests market is estimated at USD 102.2 million in 2026 and is forecast to expand at a CAGR of 5.0% to reach USD 166.4 million by 2036.
• The market covers ELISA kits, rapid diagnostic tests, molecular PCR assays, and confirmatory tests. Growth is shaped by expanding blood screening mandates, rising clinical recognition, and growing molecular testing demand.

Summary of Hepatitis E Diagnostic Tests Market

• Market Snapshot
  • In 2025, the global Hepatitis E Diagnostic Tests Market was valued at approximately USD 97.3 million.
  • The market is estimated to reach USD 102.2 million in 2026 and is projected to attain USD 166.4 million by 2036.
  • The hepatitis E diagnostic tests market is likely to expand at a CAGR of 5% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 64.2 million between 2026 and 2036.
  • ELISA kits account for 42.8% of product type share in 2026.
  • India (5.6%) and China (5.4%) are the key growth markets.
• Demand and Growth Drivers
  • Expanding blood donation screening mandates for HEV across Europe and Asia.
  • Rising clinical recognition of HEV as a cause of acute and chronic liver disease.
  • Growing molecular confirmatory testing demand through PCR-based assays.
  • Public health surveillance in endemic regions expanding testing.
  • Awareness of HEV risk in immunocompromised patients expanding clinical protocols.
• Product and Segment View
  • ELISA kits account for 42.8% of product type in 2026.
  • Clinical diagnosis accounts for 46.5% of application in 2026.
  • Hospitals account for 38.9% of end use in 2026.
• Key segmentation includes:
  • Product Type: ELISA Kits, Rapid Diagnostic Tests, Molecular PCR Assays, Confirmatory Tests
  • Application: Clinical Diagnosis, Blood Screening, Epidemiological Surveillance, Research
  • End Use: Hospitals, Diagnostic Laboratories, Blood Banks, Research Institutes
  • Technology: Serological Testing, Molecular Diagnostics, Rapid Testing
  • Sample Type: Blood, Stool, Environmental Samples
  • Distribution Channel: Direct Sales, Distributors, Online
• These products enable:
  • Serological detection of acute and past HEV infection.
  • Molecular confirmation of active viremia through PCR.
  • Blood donation screening for transfusion safety.
• Geography and Competitive Outlook
  • Europe leads in blood screening-driven demand.
  • Asia Pacific is fastest-growing with India and China leading.
  • North America shows growing clinical adoption.
  • India (5.6%) and China (5.4%) are key growth markets.
  • Key players include Wantai BioPharm and Roche.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The hepatitis E diagnostic tests market is shaped by expanding blood screening requirements creating regulation-driven demand and growing clinical recognition expanding testing protocols beyond endemic regions. Companies with validated platforms covering serological and molecular testing with multi-geography regulatory approvals will build the strongest positions.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Blood screening mandates create regulation-driven demand.
• Clinical HEV recognition increases diagnostic testing.
• Molecular testing adoption creates higher-value utilization.

Key Market Constraints

• Limited awareness in some markets.
• Lack of universal screening mandates.
• Low per-test pricing constrains revenue growth.

Key Opportunity Areas

• Screening mandate expansion to new geographies.
• Multiplex panels combining HEV with other markers.
• Point-of-care rapid testing for resource-limited settings.

Segment-wise Analysis of the Hepatitis E Diagnostic Tests Market

• ELISA kits hold 42.8% of product type in 2026.
• Clinical diagnosis at 46.5% of application.
• Molecular tests growing fastest.

Segmented by product type, application, end use, technology, sample, distribution, and region. ELISA leads by volume, molecular PCR is fastest-growing.

Which Product Type Leads?

ELISA kits at 42.8% in 2026, the established serological screening standard with high-throughput capability.

Rapid tests follow for point-of-care use. Molecular PCR assays are fastest-growing for confirmatory viremia detection.

Which Application Leads?

Clinical diagnosis at 46.5% in 2026, driven by growing HEV recognition and expanded differential diagnosis protocols.

Blood screening follows with mandatory HEV screening expanding in European blood services.

Which End Use Leads?

Hospitals at 38.9% in 2026, driven by diagnostic lab and infectious disease department procurement.

Diagnostic and reference laboratories process the highest volumes for both clinical and blood screening.

Which Product Trend is Shaping Growth?

Molecular PCR assays are the fastest-growing product as blood screening mandates increasingly require nucleic acid testing for viremic donation detection.

The shift reflects understanding that serology alone may miss window-period infections. NAT-based screening provides direct viremia detection, improving transfusion safety.

Regional Outlook Across Key Markets

• India leads at 5.6% through high endemic burden and expanding surveillance.
• China at 5.4% through blood screening programs and clinical testing.
• Brazil at 5.2% through growing awareness and testing expansion.
• Germany at 5.0% through established blood screening mandates.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Hepatitis E Diagnostic Tests Market in India

India at 5.6% CAGR, driven by high endemic burden and expanding laboratory infrastructure.

• Endemic burden sustains clinical demand.
• Public surveillance expands coverage.
• Lab growth improves access.

Hepatitis E Tests Market in Germany

Germany at 5.0% CAGR through mandatory blood screening and clinical recognition.

• Mandatory screening sustains regulation-driven demand.
• Clinical recognition expansion increases hospital testing.
• Reference lab networks maintain structured volumes.

USA Hepatitis E Tests Outlook

The U.S. at 4.8% CAGR through growing awareness and immunocompromised patient testing.

• Awareness expansion increases diagnostic testing.
• Immunocompromised testing creates targeted demand.
• Potential screening mandates could accelerate growth.

China Hepatitis E Tests Assessment

China at 5.4% CAGR through blood screening and molecular testing expansion.

• Blood screening creates structured procurement.
• Endemic prevalence sustains diagnostic demand.
• Molecular capability expansion supports confirmatory testing.

Competitive Benchmarking and Company Positioning

Hepatitis E Diagnostic Tests Market Analysis By Company

• Wantai BioPharm and Roche hold strong positions through validated ELISA and molecular platforms.
• PerkinElmer, Altona Diagnostics, and ELITechGroup compete through molecular expertise and blood screening positions.
• Regulatory approval breadth and blood screening validation are key differentiators.

Wantai leads in ELISA; Roche and Altona in molecular testing. Blood screening validation is the primary barrier.

Priorities include expanding regulatory approvals and developing multiplex panels.

Key Companies in the Hepatitis E Diagnostic Tests Market

• Wantai BioPharm and Roche lead with broad HEV diagnostic portfolios.
• PerkinElmer, Altona, and ELITechGroup hold strong molecular positions.
• MP Biomedicals, Dia.Pro, Primerdesign, Mikrogen, and Fortress compete through specialized offerings.

Recent Industry Developments

• Wantai BioPharm / HEV Diagnostic Portfolio Expansion (2025)
  • Wantai expanded its HEV diagnostic portfolio, maintaining leadership in ELISA kits and rapid tests with multi-geography regulatory approvals.
• Altona Diagnostics / PCR Platform Enhancement (2025)
  • Altona updated its RealStar HEV RT-PCR assay, supporting blood screening and clinical confirmatory testing across European laboratories.
• Roche Holding AG / Blood Screening Integration (2025)
  • Roche continued integrating HEV testing into blood screening platforms supporting expanding mandatory screening requirements.

Leading Companies Shaping the Hepatitis E Diagnostic Tests Market

• F. Hoffmann-La Roche Ltd
• Wantai BioPharm
• PerkinElmer, Inc.
• Altona Diagnostics
• MP Biomedicals LLP
• Dia.Pro Diagnostic Bioprobes srl
• ELITechGroup
• Primerdesign Ltd
• Mikrogen GmbH
• Fortress Diagnostics

Sources and Research References

• Wantai BioPharm. HEV diagnostic portfolio.
• Altona Diagnostics. RealStar HEV platform.
• WHO. Hepatitis E prevalence data.
• ECDC. HEV screening recommendations.
• Primary interviews across diagnostic companies and laboratory directors.
• This bibliography is not exhaustive.

Key Questions This Report Addresses

• Market size?
• Growth rate?
• Leading product type?
• Leading application?
• Growth drivers?
• Blood screening influence?
• Why India and China?
• Molecular testing expansion?
• Fastest countries?
• Key companies?
• Blood screening role?
• Forecast methodology?

Hepatitis E Diagnostic Tests Market Definition

The market covers IVD products for HEV detection through serological, molecular, and rapid methods.

Hepatitis E Diagnostic Tests Market Inclusions

• Scope covers forecasts across product type, application, end use, technology, sample type, distribution, and region.
• Regional analysis based on HEV prevalence and blood screening policies.
• Pricing across test formats.
• Competitive landscape.

Hepatitis E Diagnostic Tests Market Exclusions

• Excludes hepatitis A, B, C, D tests.
• Excludes liver function tests.
• Excludes HEV vaccines.
• Excludes environmental water testing equipment.

Hepatitis E Diagnostic Tests Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 120+ secondary sources and benchmarks 55+ company product portfolios.
• Market sizing covers 30+ countries through a demand-side model.
• Key inputs include disease prevalence, treatment volumes, pricing data, and regional healthcare spending.
• The model cross-checks demand with prescription/shipment data, pricing trends, and product launches.
• Primary validation includes 25+ interviews across manufacturers, clinicians, and procurement teams.
• Final estimates go through volume checks and sensitivity testing.